Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling

Zoltan N. Oltvai, Susan E. Harley, David Koes, Stephen Michel, Erica D. Warlick, Andrew C. Nelson, Sophia Yohe, Pawel Mroz

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Somatic mutations in hotspot regions of the cytosolic or mitochondrial isoforms of the isocitrate dehydrogenase gene (IDH1 and IDH2, respectively) contribute to the pathogenesis of acute myeloid leukemia (AML) by producing the oncometabolite 2-hydroxyglutarate (2-HG). The allosteric IDH1 inhibitor, ivosidenib, suppresses 2-HG production and induces clinical responses in relapsed/refractory IDH1-mutant AML. Herein, we describe a clinical case of AML in which we detected the neomorphic IDH1 p.R132C mutation in consecutive patient samples with a mutational hotspot targeted next-generation sequencing (NGS) assay. The patient had a clinical response to ivosidenib, followed by relapse and disease progression. Subsequent sequencing of the relapsed sample using a newly developed all-exon, hybrid-capture-based NGS panel identified an additional IDH1 p.S280F mutation known to cause renewed 2-HG production and drug resistance. Structural modeling confirmed that serine-To-phenylalanine substitution at this codon sterically hinders ivosidenib from binding to the mutant IDH1 dimer interface and predicted a similar effect on the pan-IDH inhibitor AG-881. Joint full-exon NGS and structural modeling enables monitoring IDH1 inhibitor-Treated AML patients for acquired drug resistance and choosing follow-up therapy.

Original languageEnglish (US)
Article numbera006007
JournalCold Spring Harbor Molecular Case Studies
Issue number2
StatePublished - Apr 2021

Bibliographical note

Publisher Copyright:
© 2021 Cold Spring Harbor Laboratory Press. All rights reserved.


Dive into the research topics of 'Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling'. Together they form a unique fingerprint.

Cite this